10-Q · May 12, 2026
Palisade Bio, Inc. reported a significant increase in research and development expenses of approximately $5.4 million for the period ended March 31, 2026, leading to a net loss of $9.6 million compared to a loss of $2.2…
Earnings analysis · 10-Q
PALI earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Palisade Bio is transitioning PALI-2108 from Phase 1 into Phase 2, supported by FDA IND clearance and a planned approximately 204-patient ASCENTRA-UC trial. Financially, Q2 revenue was $0.5 million from a license…
Read full summary
Palisade Bio is transitioning PALI-2108 from Phase 1 into Phase 2, supported by FDA IND clearance and a planned approximately 204-patient ASCENTRA-UC trial. Financially, Q2 revenue was $0.5 million from a license milestone, while operating expenses rose to $12.198 million and first-half operating cash burn increased to $11.493 million. The $125.2 million cash balance provides a substantial near-term runway, but persistent losses, an unresolved material weakness, supplier concentration and potential BIOSECURE Act restrictions remain significant risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.05
- Segment
- One operating and reportable segment: research and development of novel therapeutics; license revenue was $0.5 million in Q2 2026 versus $0 in Q2 2025.
- Segment
- PALI-2108 program expenses were $4.4 million in Q2 2026 versus $1.2 million in Q2 2025.
- Segment
- Other research and development expenses were $3.0 million in Q2 2026 versus $0.4 million in Q2 2025.
- Segment
- General and administrative expenses were $4.8 million in Q2 2026 versus $1.2 million in Q2 2025.
What stood out
-
PALI-2108 Advances to Phase 2
The FDA cleared the PALI-2108 IND on June 29, 2026, enabling the global Phase 2 ASCENTRA-UC trial. Management expects to enroll approximately 204 patients and initiate enrollment in the second half of 2026.
-
Milestone License Revenue Recognized
License revenue was $0.5 million in Q2 2026 versus $0 in Q2 2025, reflecting a milestone under the Newsoara Co-Development Agreement. The company remains a pre-product-revenue business with no revenue from product sales.
-
EPS Improved Despite Higher Spending
Diluted EPS improved to $(0.05) from $(0.58) in Q2 2025, although net loss increased to $10.574 million from $2.784 million because operating expenses rose to $12.198 million from $2.843 million.
-
Strong Cash Runway for Clinical Milestones
Cash and cash equivalents were $125.172 million at June 30, 2026, down from $133.385 million at December 31, 2025. Management believes this balance funds operations through major clinical milestones in 2027 and early 2028.
-
Clinical Investment Accelerated
PALI-2108 program expenses increased to $4.4 million from $1.2 million, including clinical operations costs of $2.3 million versus $0.7 million and CMC costs of $0.8 million versus $0.4 million.
-
R&D Ramp Drives Cash Usage
Net cash used in operating activities increased to $11.493 million for the first six months of 2026 from $4.150 million in the prior-year period. Stock-based compensation contributed $9.082 million of non-cash expense.
What to watch
-
Longer-Term Funding Requirement
The company used $11.493 million in operating cash during the first six months of 2026 and stated that it will require additional financing beyond the planned early-2028 readout to support potential Phase 3 development and commercialization.
-
Material Weakness Remains
A material weakness in internal control over financial reporting remained present as of June 30, 2026, and disclosure controls and procedures were concluded to be ineffective. The weakness relates to financial close controls, segregation of duties, journal entries and account reconciliations.
-
Phase 2 Execution Risk
Phase 2 ASCENTRA-UC is expected to enroll approximately 204 patients, with primary efficacy results expected in the second half of 2027; delays in enrollment, trial execution or unsuccessful results could materially affect the program.
-
Chinese Supplier and BIOSECURE Risk
The company relies on WuXi AppTec for PALI-2108 API manufacturing. WuXi AppTec was added to the U.S. Department of Defense's Chinese military companies list in June 2026, potentially placing it within the BIOSECURE Act framework and creating future federal procurement restrictions.
-
Concentrated API Supply
The company has only two qualified suppliers for PALI-2108 API and does not plan to establish internal manufacturing capabilities. Supply shortages, quality problems or regulatory restrictions could delay clinical drug production.
-
Equity Dilution Risk
Common shares outstanding increased to 173,595,201 at June 30, 2026 from 159,444,017 at December 31, 2025, while 51,661,394 warrants remained outstanding and exercisable, creating potential future dilution.
Management's outlook
No numeric revenue or EPS guidance was provided. Management said $125.2 million of cash and cash equivalents should fund operations through the primary ASCENTRA-UC efficacy readout expected in the second half of 2027 and the planned ASCENTRA-CD readout expected in early 2028. Management anticipates initiating ASCENTRA-UC enrollment in the second half of 2026 and submitting the ASCENTRA-CD IND in the second half of 2026.
Earlier filings 4
10-K · March 20, 2026
Palisade Bio is a clinical‑stage biotech focused on oral, colon‑targeted PDE4 prodrugs with lead candidate PALI‑2108. The company completed Phase 1 dosing (89 subjects across SAD/MAD/FE and five UC patients) and…
10-Q · August 11, 2025
Palisade Bio reported a smaller net loss in 2025 Q2: net loss of $2.784 million (-$0.58/share) versus $4.080 million (-$3.32/share) in 2024 Q2, driven by lower R&D and G&A spending. Cash declined to $5.4 million at June…
10-Q · May 12, 2025
Palisade Bio reported a narrower net loss of $2,230,000 for the three months ended March 31, 2025 versus $3,527,000 in Q1 2024, driven by lower R&D spend and reduced total operating expenses. Cash and cash equivalents…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.